G9a, a lysine methyltransferase, was investigated by Bellver-Sanchis et al., who proposed a candidate G9a inhibitor, referred to as compound F., providing a lead for G9a inhibitor design and demonstrating their involvement in reducing Alzheimer’s disease (AD) (122). Here, EHMT2 is linked to early-onset autosomal dominant Alzheimer disease.